Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Grants Marketing Approval to the Praxis Extended RAS Panel

NGS test to aid in identification of patients who may be eligible for treatment with panitumumab
07 Jul 2017
Personalised medicine;  Anticancer agents & Biologic therapy

On 29 June 2017, the US Food and Drug Administration (FDA) granted marketing approval to the Praxis Extended RAS Panel (Illumina, Inc.), a next generation sequencing (NGS) test to detect certain genetic mutations in RAS genes in tumour samples of patients with metastatic colorectal cancer (mCRC). The test is used to aid in the identification of patients who may be eligible for treatment with panitumumab (VECTIBIX, Amgen, Inc.).

This is the first FDA-approved NGS test that can detect multiple RAS gene mutations for colorectal cancer in a single test.

The Praxis Extended RAS Panel detects the presence of 56 specific mutations in RAS genes (KRAS exons 2, 3, and 4 and NRAS exons 2, 3, and 4) in the tumour tissue of patients with mCRC. If the Praxis Extended RAS Panel result indicates that a mutation is present in the CRC tissue, then panitumumab is not recommended. If the Praxis Extended RAS Panel does not detect a mutation (presumed to be RAS mutation-negative), then panitumumab may be an appropriate treatment.

The safety and effectiveness of the Praxis Extended RAS Panel was studied retrospectively using available specimens from mCRC patients enrolled in a multi-centre clinical trial that evaluated panitumumab plus FOLFOX to FOLFOX alone. Progression-free survival and overall survival in wild-type RAS patients demonstrated that the efficacy of panitumumab in patients whose tumours do not have a KRAS or NRAS mutation is supported. Analytical validation demonstrated that the panel performs consistently and accurately in the detection of the select KRAS and NRAS mutations in mCRC patients.
Panitumumab’ s product labelling has been modified to align the indication for panitumumab and intended use for the Praxis Extended RAS Panel, stating that panitumumab is indicated in first-line therapy in combination with FOLFOX for patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) mCRC. Panitumumab is also indicated as monotherapy for patients with wild-type RAS mCRC following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.

Instructions for use of the Praxis Extended RAS Panel is available here.  

Full prescribing information for panitumumab is available here.  

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

Last update: 07 Jul 2017

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.